Skip to main content

Ovarian Cancer Therapy – Innovative Models Prolong Survival

Objective

"About 75% of advanced epithelial ovarian cancer (EOC) patients respond to first-line surgery and chemotherapy but most relapse and ultimately acquire platinum resistance which soon leads to death. Relapsed high grade serous ovarian cancer (HGSOC) is the single main cause of EOC-related morbidity and mortality (despite the fact that HGSOC is highly chemosensitive). We hypothesize that the primary tumour includes a small population of resistant cells that are ultimately responsible for relapse and that by targeting this population front-line we may prolong disease-free survival or even achieve cure. OCTIPS will use unique retrospective and novel prospective paired tumour samples collected at the time of diagnosis and relapse to identify and validate molecules and pathways responsible for relapse. This identification will employ cutting edge high throughput multiplatform analyses such as next generation sequencing, mRNA and miRNA expression arrays and SNP array. Known and newly defined molecules or pathways will be evaluated in innovative integrated cancer model systems, utilising cell lines and avian egg and murine xenografts. New therapies to target these molecules and pathways will be developed and validated in these model systems. In order to translate these findings into patient benefit, agents that target the relapsing cell population will be tested for tolerability, efficacy, ability to combine with first line chemotherapy and then in randomised first line trials by the OCTIPS consortium.
By translating the clinical observation of treatment failures into innovative cancer models that mimic relapsed ovarian cancer, we will validate improved front-line therapeutic strategies to help prolong patient survival. The impact of this application is that it defines a highly rigorous approach to integrate the bedside to bench to bedside paradigm, leading to novel prognosis-changing strategies for the treatment of ovarian cancer patients."

Call for proposal

FP7-HEALTH-2011-two-stage
See other projects for this call

Coordinator

MEDIZINISCHE UNIVERSITAET WIEN
Address
Spitalgasse 23
1090 Wien
Austria
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 533 492,25
Administrative Contact
Dan Cacsire Casstillo-Tong (Prof.)

Participants (10)

CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Germany
EU contribution
€ 241 368
Address
Chariteplatz 1
10117 Berlin
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Eveline Fräßdorf (Ms.)
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
EU contribution
€ 433 000
Address
Oude Markt 13
3000 Leuven
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Tine Heylen (Ms.)
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
United Kingdom
EU contribution
€ 324 045,40
Address
South Kensington Campus Exhibition Road
SW7 2AZ London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Tatjana Palalic (Ms.)
THE UNIVERSITY OF EDINBURGH
United Kingdom
EU contribution
€ 285 752
Address
Old College, South Bridge
EH8 9YL Edinburgh
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Valerie Renton (Ms.)
EMERGENTEC BIODEVELOPMENT GMBH
Austria
EU contribution
€ 230 986
Address
Gersthofer Strasse 29-31
1180 Vienna
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Bernd Mayer (Dr.)
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands
EU contribution
€ 334 561,38
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Arjan P Bandel (Mr.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 291 012
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
Administrative Contact
Vincent Boyer (Mr.)
INNOVO MIMETICS LIMITED
Israel
EU contribution
€ 149 360
Address
Palmach Suite 2 68
92587 Jerusalem
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jonathan Goldstein (Mr.)
ALCEDIS GMBH
Germany
EU contribution
€ 60 300
Address
Winchesterstrasse 2
35394 Giessen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Elke Heidrich-Lorsbach (Dr.)
CYCLACEL LIMITED
United Kingdom
EU contribution
€ 115 425
Address
James Lindsay Place Unit 1
DD1 5JJ Dundee
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
David Blake (Dr.)